Twist Bioscience Co. (NASDAQ:TWST) COO Sells $140,400.75 in Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 2,845 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total transaction of $140,400.75. Following the transaction, the chief operating officer now owns 269,199 shares of the company’s stock, valued at approximately $13,284,970.65. The trade was a 1.05 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Patrick John Finn also recently made the following trade(s):

• On Thursday, January 23rd, Patrick John Finn sold 2,422 shares of Twist Bioscience stock. The stock was sold at an average price of $50.17, for a total transaction of $121,511.74.
• On Friday, January 3rd, Patrick John Finn sold 229 shares of Twist Bioscience stock. The stock was sold at an average price of $45.59, for a total transaction of $10,440.11.
• On Monday, November 11th, Patrick John Finn sold 10,340 shares of Twist Bioscience stock. The stock was sold at an average price of $48.00, for a total transaction of $496,320.00.

Twist Bioscience Stock Performance

Shares of NASDAQ:TWST opened at $53.70 on Friday. The stock’s fifty day simple moving average is $48.84 and its two-hundred day simple moving average is $46.32. Twist Bioscience Co. has a 1-year low of $27.41 and a 1-year high of $60.90.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.27% and a negative net margin of 66.69%. The business had revenue of $88.70 million for the quarter, compared to analysts’ expectations of $86.96 million. During the same period last year, the business earned ($0.75) EPS. The business’s revenue was up 24.1% on a year-over-year basis. As a group, research analysts expect that Twist Bioscience Co. will post -2.27 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Barclays reduced their price objective on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research report on Tuesday, November 19th. Wolfe Research assumed coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective for the company. JPMorgan Chase & Co. raised their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research report on Tuesday. Scotiabank raised their price objective on shares of Twist Bioscience from $54.00 to $62.00 and gave the stock a “sector outperform” rating in a research report on Tuesday. Finally, TD Cowen reissued a “buy” rating and issued a $58.00 price target on shares of Twist Bioscience in a research report on Tuesday, November 26th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, Twist Bioscience presently has an average rating of “Moderate Buy” and an average price target of $53.80.

Hedge Funds Weigh In On Twist Bioscience

Large investors have recently bought and sold shares of the stock. Van ECK Associates Corp lifted its stake in Twist Bioscience by 56.4% during the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after acquiring an additional 267 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Twist Bioscience during the 3rd quarter worth $34,000. Signaturefd LLC raised its stake in shares of Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after purchasing an additional 306 shares during the period. US Bancorp DE raised its stake in shares of Twist Bioscience by 72.0% during the 4th quarter. US Bancorp DE now owns 1,436 shares of the company’s stock worth $67,000 after purchasing an additional 601 shares during the period. Finally, Beaird Harris Wealth Management LLC bought a new stake in shares of Twist Bioscience during the 3rd quarter worth $95,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.